Success Stories: EB1A Approval Secured for a Biomedical Scientist from India, Advancing Global Cancer Research
Client’s Testimonial:
“I am very thankful to the team’s support and continuous guidance throughout my EB1 process, as well as my previous NIW process. They are very professional, meticulous, responsive, and very detailed. They know all the immigration processes in depth and guide you with all the details. I appreciate all their help and recommend them to anyone going through the same journey.”
On May 15th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Staff Scientist in the Field of Translational Science (Approval Notice).
General Field: Translational Science
Position at the Time of Case Filing: Staff Scientist
Country of Origin: India
State of Residence at the Time of Filing: Washington
Approval Notice Date: May 15th, 2025
Processing Time: 1 year, 3 months, 8 days (Premium Processing Requested)
Case Summary:
A pioneering researcher in the field of translational science and therapeutics from India recently received I-140 approval under the EB1A (Alien of Extraordinary Ability) category, affirming her exceptional contributions to cancer biomarker discovery and therapeutic target development. The petition, initially filed on February 7, 2024, was officially approved on May 15, 2025. This case reflects not only scientific excellence but also the strategic advocacy required for high-standard immigration success.
Uncovering Molecular Mechanisms Behind Cancer and Disease
Our client’s research has consistently broken ground in cancer proteomics, myeloid malignancies, and biomolecular diagnostics. Her work spans the identification of biomarkers in acute myeloid leukemia, investigation of protein mis-splicing mechanisms, and the analysis of therapeutic targets in retinoblastoma and other cancers. Additionally, she has led impactful studies in veterinary proteomics, including the detection of novel diagnostic proteins in bovine urine.
She is currently employed in a U.S.-based medical research institute, where she continues to expand her work in biomarker-based cancer stratification and targeted therapies.
Objective Evidence of Extraordinary Ability
In building her EB1A petition, we demonstrated through rigorous documentation that she is one of the few researchers in her field to have achieved such a comprehensive and sustained impact:
● 18 peer-reviewed articles and 1 conference abstract published in top-ranked journals, including Blood, Haematologica, and Journal of Proteomics;
● 350 citations across scholarly literature, with her most-cited paper ranking among the top 1% most cited in Biology & Biochemistry for its year of publication;
● 10 completed peer reviews for high-impact journals such as Biomarker Research and Journal of Hematology and Oncology, reflecting her role as a trusted authority;
● Funding support from prestigious institutions, including the National Cancer Institute and National Agricultural Science Fund, confirms the societal and scientific merit of her work.
● Her published work has been relied upon by researchers in over 40 countries, spanning Europe, Asia, the Americas, and beyond.
Endorsements from International Experts
The petition included four letters of recommendation from globally respected scientists who offered compelling testimonials to her international recognition and significance in the field. These recommenders, based in the U.S., Spain, and Mexico, emphasized the originality and reach of her research.
One recommender wrote:
“Her contributions to the field—particularly in the discovery of splicing-associated cancer phenotypes and molecular diagnostics—have not only influenced clinical research strategies but also informed therapeutic innovations currently being explored in hematological malignancies.”
One Approval, Many Frontiers
This approval under the EB1A category marks a significant milestone in the client’s journey. She even received her NIW approval with us in the past. Her research continues to illuminate new pathways for early cancer detection, precision medicine, and innovative immunotherapies.
We are proud to have played a role in presenting a case that did justice to her work. As she continues to contribute to biomedical science from within the United States, we have no doubt that her efforts will deliver tangible benefits to patients, clinicians, and the global scientific community.